Menglong, Hou
Loading...
Товч нэр
Menglong, Hou
Бүтэн нэр
Menglong Hou
Латин нэр
Menglong Hou
Албан тушаал
Судлаач
4 results
Now showing 1 - 4 of 4
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, HLF and PPARα axis regulates metabolic-associated fatty liver disease through extracellular vesicles derived from the intestinal microbiota.(2025-04); Liu, MengkuanScopus© Citations 20 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Arbutin alleviates fatty liver by inhibiting ferroptosis via FTO/SLC7A11 pathway.(2023-12)Scopus© Citations 103 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Corrigendum to "Arbutin alleviates fatty liver by inhibiting ferroptosis via FTO/ SLC7A11 pathway" [Redox Biol. 68 (2023) 102963].(2024-02)Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Aloesin improves metabolic associated fatty liver disease and obesity by targeting TGFBR1(2026-04); Liao, QichaoBACKGROUND: Metabolic associated fatty liver disease (MAFLD) is a chronic liver condition with a high global prevalence. Obesity and its associated insulin resistance are among the main risk factors for MAFLD, for which no effective clinical treatments are currently available. Aloesin, a natural chromone compound derived from Aloe vera, has anti-inflammatory, antioxidant, anticancer, and antidiabetes activity. However, its involvement in MAFLD has not been systematically studied. PURPOSE: This study investigated the effectiveness of aloesin against MAFLD and obesity and elucidated its potential molecular mechanism. METHODS: Aloesin was added to the high-fat diet-of an induced mouse model and to oleic acid/palmitic acid-induced HepG2 cells to explore its effect on lipid metabolism. Molecular targets were identified by reverse docking, cellular thermal shift assay (CETSA), and drug affinity responsive target stability (DARTS). RESULTS: Aloesin significantly reduced lipid accumulation in hepatocytes in both the high-fat diet-induced MAFLD mouse model and the oleic acid/palmitic acid-induced HepG2 cells. It also alleviated oxidative stress and energy metabolism disorders and decreased the body fat mass in mice fed the high-fat diet, which ameliorated the pathological features of MAFLD and obesity. Target prediction and validation identified TGFBR1 as a direct target of aloesin, which was confirmed by CETSA and DARTS. Functional experiments demonstrated that overexpression of TGFBR1 increased lipid accumulation and metabolic disturbances, which were reversed by aloesin. CONCLUSION: Aloesin improved lipid deposition and slowed the progression of MAFLD by targeting TGFBR1. The results support its potential application for the prevention and treatment of MAFLD.